Evommune reports positive Phase 2a top-line data for EVO301 in atopic dermatitis

Evommune, Inc.

Primary endpoint met: 99.8% of posterior distribution exceeded 8% improvement threshold vs placebo.
Frequentist analysis showed p<0.01 at weeks 4, 8, 12; 33% placebo-adjusted EASI reduction at week 12.
23% of EVO301 patients achieved vIGA-AD 0/1 at week 12 vs 0% placebo.
EVO301 well tolerated; no related serious/severe AEs or treatment discontinuations.
Company plans Phase 2b dose-ranging trial with subcutaneous formulation; evaluating ulcerative colitis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.